Recently, prooncogenic activity of NRF2 in cancer development, cancer progression, cancer cell growth and angiogenesis, and NRF2 involvement in anticancer therapy resistance is also under observation [2,36,37,38,39]. The gene discussed is NFE2L2; the disease is cancer.